Replies to post #183627 on Biotech Values

[hirogen]

XOMA -

Both of the above mean it is less likely the company is applying lessons learned to their other uveitis trials.

That's it in a nutshell. I don't think XOMA, or Servier for that matter, recognize the risks to the trial by allowing physicians such wide discretion. The response seems to be we'll just up our site monitoring to assure data integrity and any off effects will be captured by the sensitivity analyses. I understand the desire to help the individual patient particularly when suffering, hence the tough call, but those involved seems to be missing the bigger picture.

I seriously hope they hire a consultant like Master or Flemming.

Yeah, but most likely not going to happen. By the tone of the conference call, they believe they have things covered.

p.s. thanks for the comments on XMet, still (slowly) working my way through it.